Cover Page |
May 17, 2026 |
|---|---|
| Cover [Abstract] | |
| Amendment Flag | true |
| Entity Central Index Key | 0001662774 |
| Document Type | 8-K/A |
| Document Period End Date | May 17, 2026 |
| Entity Registrant Name | QUINCE THERAPEUTICS, INC. |
| Entity Incorporation, State or Country Code | DE |
| Entity File Number | 001-38890 |
| Entity Tax Identification Number | 90-1024039 |
| Entity Address, Address Line One | 611 Gateway Boulevard |
| Entity Address, Address Line Two | Suite 273 |
| Entity Address, City or Town | South San Francisco |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94080 |
| City Area Code | 415 |
| Local Phone Number | 910-5717 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, par value $0.001 per share |
| Trading Symbol | QNCX |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Amendment Description | This Amendment No. 2 on Form 8-K/A (this “Amendment No. 2”) amends the Current Report on Form 8-K filed by Quince Therapeutics, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on May 18, 2026 (the “Original Filing”), as amended by Amendment No. 1 to the Original Filing, filed by the Company with the SEC on May 18, 2026, in which the Company reported, among other events, the completion of the acquisition of Orphai Therapeutics, LLC, a Delaware limited liability company (formerly Orphai Therapeutics, Inc., a Delaware corporation) (“Orphai Subsidiary”) and Orphai Holdings Therapeutics, Inc. (“HoldCo”). This Amendment No. 2 is filed to (i) update the information in Item 9.01(a) of the Original Report to include the audited financial statements of Orphai as of and for the years ended December 31, 2025 and 2024 and the unaudited interim condensed consolidated financial statements of Orphai as of and for the three months ended March 31, 2026 and 2025; and (ii) update the information in Item 9.01(b) of the Original Report to include the unaudited pro forma condensed consolidated financial information of the Company as of and for the three months ended March 31, 2026 and the year ended December 31, 2025. The financial statements have been presented for Orphai, which was the entity that held all of the assets acquired. None of the assets acquired were attributable to HoldCo. Additionally, this Amendment No. 2 is filed to incorporate by reference business and risk factor information of Orphai. This Amendment No. 2 does not amend any other item of the Original Report. Capitalized terms used but not defined herein have the meanings given to them in the Original Report. In accordance with Rule 12b-15 of the Securities Exchange Act of 1934, as amended, the complete text of Item 9.01 (as amended) is included herein. |